Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia.

Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia. Blood. 2012 Jun 21; 119(25):5989-95.

View in: PubMed

Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.